(UroToday.com) The testis cancer panel discussion on biomarkers at the Society of Urologic Oncology (SUO) 2020 virtual program included Dr. Aditya Bagrodia from UT Southwestern Medical Center discussing the ongoing and upcoming microRNA-based trials for patients with germ cell tumors.
(UroToday.com) In a session of the Best Prostate Cancer Poster Presentations at this year’s Society of Urologic Oncology (SUO) virtual annual meeting, Dr. Nitin Yerram presented work from the National Cancer Institute examining the role of deep learning algorithms for pathological analysis of whole-mount pathology specimens.
(UroToday.com) In the second Prostate Cancer session at this year’s Society of Urologic Oncology (SUO) virtual annual meeting, Dr. Kara Maxwell provided an overview of biomarkers for patients with advanced prostate cancer. While many urologists are familiar with and may use, tissue-based biomarkers in early disease, there is an increasing number of actionable biomarkers in advanced […]
(UroToday.com) Following Dr. Hussain’s presentation on olaparib in metastatic castration-resistant prostate cancer (mCRPC) in the second prostate cancer session at the 2020 Society of Urologic Oncology (SUO) Annual Virtual Meeting, Dr. Daniel Spratt provided a counterpoint talk entitled, “PROfound-ly Misguided: The Side of the Story They Don’t Want You to Hear.”
(UroToday.com) In a point and counterpoint format at the 2020 Society of Urologic Oncology (SUO) virtual meeting discussing whether PSMA PET-CT is ready for prime-time use, Dr. Tanya Dorff took the “pro” point approach that prostate-specific membrane antigen (PSMA) PET-CT is ready for prime-time use and may fill an unmet need in the treatment of prostate […]
(UroToday.com) The State-of-the-Art Lecture at the 2020 Society of Urologic Oncology (SUO) annual virtual winter meeting was provided by Dr. Duke Herrell of Vanderbilt University who discussed the past, present, and future of surgical robotics and oncology. For decades “surgery” was an open body cavity, with exposed organs, and relying heavily on the visual plus manual […]
(UroToday.com) The Society of Urologic Oncology (SUO) 2020 virtual meeting featured a session examining the new and emerging agents in bladder cancer chaired by Dr. Neal Shore, which included a presentation by Dr. Ashish Kamat discussing the evolving role of checkpoint inhibition in nonmuscle-invasive bladder cancer (NMIBC).
(UroToday.com) In this presentation, Dr. Jim Hu gave an outline on prostate biopsy risks, guideline recommendations, contemporary studies of prostate biopsy, and presented high-level evidence to guide best practice when performing prostate biopsies.
(UroToday.com) The second prostate cancer session was centered around the emerging management of metastatic prostate cancer. Dr. Cora Sternberg was invited to present on the outcomes of the PROSPER trial and specifically its most recent interim analysis.
(UroToday.com) At the 2020 virtual Society of Urologic Oncology’s (SUO) prostate cancer session, Dr. Declan Murphy discussed the role of prostate-specific membrane antigen (PSMA) scanning in prostate cancer staging. Dr. Declan Murphy states that PSMA PET/CT is an obvious challenger to conventional imaging.
